


PHARMACEUTICAL 2023

CytoDyn Inc. Rank 442 of 446









PHARMACEUTICAL 2023

CytoDyn Inc. Rank 442 of 446



The relative strengths and weaknesses of CytoDyn Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytoDyn Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 179% points. The greatest weakness of CytoDyn Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 349% points.

The company's Economic Capital Ratio, given in the ranking table, is -489%, being 532% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	10,515
Cost of Goods Sold	53
Intangible Assets	132
Liabilities, Current	123,161
Liabilities, Non-Current	422
Other Assets	18,465
Other Compr. Net Income	0
Other Expenses	139,687
Other Liabilities	0
Other Net Income	0
Other Revenues	266
Property and Equipment	73
Research and Development	27,043
Selling, General and Administrative Expense	44,303

Output Variable	Value in 1000 USD
Assets	29,185
Liabilities	123,583
Expenses	211,086
Revenues	266
Stockholders Equity	-94,398
Net Income	-210,820
Comprehensive Net Income	-210,820
Economic Capital Ratio	-489%

